UBS’s Catalyst Pharmaceutical CPRX Stock Holding History

UBS’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$6K	Buy	1,900 +1,500	+375%	+$3.92K	﹤0.01%	9271
2014 Q2	$1K	Sell	400 -1,000	-71%	-$2.14K	﹤0.01%	10194
2014 Q1	$3K	Buy	+1,400	New	+$2.93K	﹤0.01%	9825

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS's CPRX Position: Q2 2014 in Review

UBS sold out of Catalyst Pharmaceutical (CPRX) in Q2 2014, closing a stake of 32,551 shares — an estimated $69.5K sold.

UBS first reported a position in CPRX in Q2 2013 and held it in 2 quarters. The position peaked at $74K in Q1 2014. 47 funds tracked by Wall St. Rank hold CPRX as of Q2 2014.

UBS reported no remaining Catalyst Pharmaceutical position as of Q2 2014 after selling out during the quarter.
UBS sold 32,551 Catalyst Pharmaceutical shares in Q2 2014, an estimated $69.5K.
UBS first reported a position in Catalyst Pharmaceutical in Q2 2013 and held it in 2 quarters.
UBS's Catalyst Pharmaceutical position peaked at $74K in Q1 2014.
47 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.